A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
Saved in:
| Title: | A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. |
|---|---|
| Authors: | Saijo A; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Department of Internal Medicine, Tokushima Prefecture Naruto Hospital, Tokushima, Japan., Ogino H; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan., Butowski NA; Department of Neurological Surgery, University of California, San Francisco, CA, USA., Tedesco MR; Department of Neurology, University of California, San Francisco, CA, USA., Gibson D; Department of Neurological Surgery, University of California, San Francisco, CA, USA., Watchmaker PB; Department of Neurological Surgery, University of California, San Francisco, CA, USA., Okada K; Department of Neurological Surgery, University of California, San Francisco, CA, USA., Wang AS; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Department of Pathology, University of California, San Francisco, CA, USA., Shai A; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Department of Pathology, University of California, San Francisco, CA, USA., Salazar AM; Oncovir Inc., Washington, DC, USA., Molinaro AM; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.; Immatics Biotechnologies GmbH, Tuebingen, Germany., Rabbitt JE; Department of Neurological Surgery, University of California, San Francisco, CA, USA., Shahin M; Department of Neurological Surgery, University of California, San Francisco, CA, USA., Perry A; Department of Pathology, University of California, San Francisco, CA, USA., Clarke JL; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Department of Neurology, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA., Taylor JW; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Department of Neurology, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA., Daras M; Department of Neurological Surgery, University of California, San Francisco, CA, USA., Oberheim Bush NA; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Department of Neurology, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA., Hervey-Jumper SL; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA., Phillips JJ; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.; Department of Pathology, University of California, San Francisco, CA, USA., Chang SM; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA., Hilf N; Immatics Biotechnologies GmbH, Tuebingen, Germany., Mayer-Mokler A; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA., Keler T; Celldex Theraepeutics, Inc., Hampton, NJ, USA., Berger MS; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA., Okada H; Department of Neurological Surgery, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. |
| Source: | Neuro-oncology [Neuro Oncol] 2024 Feb 02; Vol. 26 (2), pp. 335-347. |
| Publication Type: | Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
